



PRECEPTORSHIP PROGRAMME

Lung Cancer

**ESMO VIRTUAL
PRECEPTORSHIP**

9-11 MARCH 2022

Multidisciplinary management, standards of care, therapeutic targets and future perspectives.

Chairs:

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Enriqueta Felip, Spain

ESMO-THE CHRISTIE VIRTUAL PRECEPTORSHIP PROGRAMME LUNG CANCER

Multidisciplinary management, standards of care and future perspectives

9-11 March 2022

CO-CHAIRS:

Fiona Blackhall, United Kingdom
Raffaele Califano, United Kingdom
Enriqueta Felip, Spain

SPEAKERS:

Andrea Ardizzoni, Italy
Paul Baas, Netherlands
Haval Balata, United Kingdom
Neil Bayman, United Kingdom
Richard Booton, United Kingdom
Clara Chan, United Kingdom
Anne-Marie Dingemans, Netherlands
John G. Edwards, United Kingdom
Simon Ekman, Sweden
Corinne Faivre-Finn, United Kingdom
Pilar Garrido López, Spain
Keith M. Kerr, United Kingdom
Rohit Kochhar, United Kingdom

Cécile Le Péchoux, France
Colin Lindsay, United Kingdom
Catherine McBain, United Kingdom
Luis Paz-Ares, Spain
Solange Peters, Switzerland
David Planchard, France
Martin Reck, Germany
Christina H. Ruhlmann, Denmark
Suresh Senan, Netherlands
Paul Taylor, United Kingdom
Fiona Thistlethwaite, United Kingdom
Giulia Veronesi, Italy
David Woolf, United Kingdom

LEARNING OBJECTIVES

- To learn about the evidence-base for lung cancer screening and novel diagnostic modalities
- To learn about the management of early-stage NSCLC and use of adjuvant treatments
- To understand the role of multi-modality treatment in locally advanced NSCLC and limited stage SCLC
- To learn about the management of patients with actionable driver mutations and novel targeted agents for advanced NSCLC
- To understand the role of immune-checkpoint blockade for lung cancer and to learn about novel immunotherapies
- To learn about treatment of NSCLC with oligometastatic disease
- To learn about the systemic treatment of mesothelioma and SCLC
- To learn about the role of supportive and palliative care for thoracic malignancies

ACCREDITATION

The programme of this event has been accredited with **13 ESMO-MORA category 1 points**. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to esmo.org

ACKNOWLEDGEMENTS

This event is supported by an unrestricted educational grant from



All timings are to be considered CET (Central European Time)

Wednesday, 9 March 2022

14:00-14:10 10'	Welcome & Introduction	Fiona Blackhall, UK Enriqueta Felip, ES Raffaele Califano, UK
14:10-14:35 25'	SESSION 1 Clinical issues	Chair/Moderator: Raffaele Califano, UK
20'	Balancing costs and clinical benefit in medical oncology	Solange Peters, CH
5'	Discussion	Faculty
14:35-15:45 70'	SESSION 2 Screening and diagnostics for lung cancer	Chair/Moderator: Raffaele Califano, UK
20'	Lung cancer screening: Pro and Contra	Haval Balata, UK
20'	EBUS TBNA in diagnosis/staging of lung cancer	Richard Booton, UK
20'	Role of pathologist in diagnosis and mutation analysis of lung cancer	Keith M. Kerr, UK
10'	Discussion	Faculty
15:45-15:55	Break	
15:55-16:25 30'	SESSION 2 - cont. Screening and diagnostics for lung cancer	Chairs/Moderators: Fiona Blackhall, UK Raffaele Califano, UK
20'	PET/CT in staging of lung cancer	Rohit Kochhar, UK
10'	Discussion	Faculty
16:25-17:55 90'	SESSION 3 Radical treatment of early stage NSCLC	Chair/Moderator: Raffaele Califano, UK
20'	Surgery for early-stage NSCLC	Giulia Veronesi, IT
20'	Stereotactic ablative RT for early-stage NSCLC	Suresh Senan, NL
20'	Adjuvant radiotherapy for completely resected early-stage NSCLC	Cécile Le Péchoux, FR
20'	Adjuvant systemic therapies for resected early-stage NSCLC	Paul Taylor, UK
10'	Discussion	Faculty
17:55-18:05 10'	Close of day 1	Fiona Blackhall, UK Raffaele Califano, UK

Thursday, 10 March 2022

14:00-16:45 160'	SESSION 4 Advanced NSCLC	Chair/Moderator: Fiona Blackhall, UK
20'	1 st line chemotherapy for advanced NSCLC	David Planchard, FR
20'	1 st line Immune-checkpoint blockade for advanced NSCLC	Luis Paz-Ares, ES
20'	2 nd line treatment for advanced NSCLC	Martin Reck, DE
20'	Treatment of EGFR mutant advanced NSCLC	Raffaele Califano, UK
10'	Discussion	Faculty
15:30-15:35	Break	
20'	Treatment of ALK and ROS1 positive advanced NSCLC	Fiona Blackhall, UK
20'	Treatment of KRAS mutant advanced NSCLC	Colin Lindsay, UK
20'	Beyond EGFR, ALK, ROS1 and KRAS: Novel molecularly driven targeted therapies in NSCLC	Simon Ekman, SE
10'	Discussion	Faculty
16:45-18:15 90'	SESSION 5 Management of mesothelioma, oligometastatic NSCLC and brain metastases	Chair/Moderator: Raffaele Califano, UK
20'	Systemic treatment of mesothelioma	Paul Baas, NL
20'	Treatment of oligometastatic NSCLC	Anne-Marie Dingemans, NL
20'	Radical treatment of brain metastases: The importance of a neuro-oncology multi-disciplinary approach	Catherine McBain, UK
20'	Supportive and palliative care in lung cancer	Christina H. Ruhlmann, DK
10'	Discussion	Faculty
18:15-18:25 10'	Close of day 2	Fiona Blackhall, UK Raffaele Califano, UK

Friday, 11 March 2022

14:00-16:10 130'	SESSION 6 SCLC and Cell Therapies	Chairs/Moderators: Raffaele Califano, UK
20'	Targeted agents in SCLC	Enriqueta Felip, ES
20'	Treatment of limited stage SCLC	Corinne Faivre-Finn, UK
20'	Chemotherapy for extensive stage SCLC	Andrea Ardizzoni, IT
20'	Immune checkpoint blockade for SCLC	Pilar Garrido López, ES
20'	Prophylactic cranial irradiation and role of thoracic RT for extensive stage SCLC	Neil Bayman, UK
20'	CAR-T and next generation cell therapies for lung cancer	Fiona Thistlethwaite, UK
10'	Discussion	Faculty
16:10-16:15	Break	

16:15-18:10 115'	SESSION 7 Locally advanced NSCLC	Chairs/Moderators: Fiona Blackhall, UK
20'	Treatment of locally advanced NSCLC in the elderly	David Woolf, UK
20'	Combined modality treatment for NSCLC with N2 disease	Clara Chan, UK
20'	Role of surgery for N2 disease	John G. Edwards, UK
10'	Discussion	Faculty
45'	Participants clinical case discussion (3x15')	Faculty

Each 15 min slot for clinical case discussion includes 10' case presentation and 5' Q&A / interactive panel discussion

18:10-18:15 5'	Conclusion and farewell	Fiona Blackhall, UK Raffaele Califano, UK
---------------------------------	--------------------------------	--

ORGANISATION AND CONTACTS

ESMO Head Office
Education Department
Via Ginevra 4
6900 Lugano
Switzerland
Email: courses@esmo.org
www.esmo.org

